(PC) Medley v. Pfitzer

District Court, E.D. California·Decided March 10, 2025·No. 2:22-cv-00227·Unknown

Opinion

THEODORA MEDLEY, No. 2:22-cv-00227 DJC SCR P Plaintiff, v. FINDINGS AND RECOMMENDATIONS S. PFITZER, et al., Defendants. Plaintiff is a state prisoner proceeding pro se and in forma pauperis in this civil rights action under 42 U.S.C. § 1983. On August 24, 2023, the previously assigned magistrate judge appointed counsel to plaintiff for the limited purpose of “investigating the claim, then drafting and filling an amended complaint.” (ECF No. 89.) Counsel filed the second amended complaint (“SAC”) on November 12, 2024 (ECF No. 100), thereby fulfilling their obligations pursuant to the limited appointment order. The SAC is now before the court for screening pursuant to 28 U.S.C. § 1915A. However, upon review, the undersigned has determined that the SAC contains misjoined claims that preclude screening at this time. To avoid prejudice to plaintiff, namely the barring of claims by the statute of limitations if they were dismissed with leave to amend, the undersigned recommends that the misjoined claims be severed and proceed in a new action consistent with the instructions below. I. Facts Relating to Medical Care and Disability Accommodations The facts forming the basis of this action occurred at California Health Care Facility, Stockton (“CHCF”), which plaintiff entered on or about February 29, 2016. (ECF No. 100 at 4, ¶ 24-25.) Plaintiff has a well-documented history of mental health and disability diagnoses dating back at least to her initial incarceration in 2000. (Id. at 3, ¶¶ 20-21.) Because she is transgender, intersex, and has diagnoses of Autism Spectrum Disorder, gender dysphoria, and Sensory Integration Disorder, plaintiff is vulnerable to and at risk of sexual victimization. (Id. at 4, ¶ 25.) Plaintiff has participated in the Department of Corrections and Rehabilitation’s (CDCR) Developmental Disability Program (DDP) since July 20, 2015. (ECF No. 100 at 4, ¶ 25.) Upon her DDP screening, plaintiff was designated DD2, which required her to receive adaptive support and accommodations. (Id.) As a DD2 she was required to be housed in a designated DDP building, unit, or wing. Plaintiff also has physical disabilities that require a lower/bottom bunk and housing on the ground floor. (Id.) In March 2016, during plaintiff’s intake processing at CHCF, she was designated as a DD2 and housed in the E1-Fox housing unit. (Id., ¶ 26.) Plaintiff was born intersex and experiences Congenital Adrenal Hyperplasia (“CAH”). In 2016 plaintiff was prescribed Liquid Nutritional Supplement (“LNS”), Glucerna 1.5, taken four times daily to accommodate her IBS-C, Autism, CAH, and other food intolerances. (ECF No. 100 at 4, ¶ 27.) When plaintiff is low weight or does not receive sufficient caloric intake, she experiences physical symptoms such as increased pain in her feet and hands and a sensation as if she is having a seizure. Plaintiff also experiences sensory issues that cause issues with her memory, increased impulsivity, and mood. (Id. at 4-5, ¶ 28.) As a result of the treatment plan that included Glucerna, plaintiff was able to gain and maintain her weight. (Id. at 5, ¶ 29.) Other LNS supplements, such as Boost and Ensure, do not have the same effect on her. (Id.) In 2018, defendant Dr. Samiinia removed plaintiff’s diagnosis of gender dysphoria and Autism Spectrum Disorder without providing a reason. As a result, plaintiff was reclassified as a DD1 in the DDP and no longer met the criteria for single cell housing. (ECF No. 100 at 5-6, ¶ 32.) One week later, Defendant Samiinia reinstated plaintiff’s diagnoses but plaintiff’s DD2 classification was not reinstated. (Id. at 6, ¶ 33.) On or about January 4, 2021, defendant Vicencio discontinued plaintiff’s prescription for Glucerna 1.5 and replaced it with another LNS, Ensure 1.5. Plaintiff had been taking Glucerna since 2018 as treatment for plaintiff’s digestive disorder. Since Ensure has half the caloric density as Glucerna, more sugar, and made plaintiff feel ill, weak, and faint multiple times. (ECF No. 100 at 8, ¶ 43.) On January 15, 2021, plaintiff was put back on the Glucerna. (Id., ¶ 44.) On March 23, 2021, plaintiff met with Dr. Suresh Hosuru. (ECF No. 100 at 9, ¶ 46.) A few days later, plaintiff was put on Ensure instead of Glucerna because it was out of stock. (Id.) On April 5, 2021, plaintiff filed a grievance regarding the change. (Id., ¶ 47.) On April 7, 2021, the Reasonable Accommodation Panel (“RAP”) denied her request for Glucerna with no acknowledgment that it was a treatment for her Autism, and thus also an accommodation. (Id., ¶ 48.) Defendants Hall, Williams, and Petersen were on the RAP that denied the request. (Id.) On April 8, 2021, plaintiff met with Melanie Henrey, who said “[she] did not know why [plaintiff] gets Glucerna.” (ECF No. 100 at 9, ¶ 49.) Plaintiff told Henrey that she had been receiving Glucerna since 2018 and it was a necessary accommodation for her diagnoses of Autism Spectrum Disorder, IBS, CAH, and other digestive disorders, as well as part of her treatment plan to gain weight and maintain a healthy body weight. During this conversation, Henrey threatened to end plaintiff’s Glucerna’s prescription because plaintiff filed a grievance. On July 3, 2021, plaintiff was weighed at 145.5 lbs., down from her typical weight of 165 lbs. (ECF No. 100 at 9, ¶ 50.) On or about July 7, 2021, plaintiff’s Glucerna prescription expired. (Id., ¶ 51.) On July 11, 2021, plaintiff’s Glucerna prescription was reinstated but instead of receiving it four times a day as she did before, she was receiving it twice per day. (Id., ¶ 52.) On or about July 10, 2021, defendant Elizabeth Byers visited plaintiff outside of her cell. Plaintiff had not previously met Byers and explained to her that due to her medical conditions, she is not able to eat the foods provided and that Glucerna has been her approved plan of care since 2018. Byers ignored plaintiff’s explanation and informed her that she could not reinstate the Glucerna prescription if plaintiff “refused to eat.” Throughout this interaction, Byers made multiple intimidating statements threatening to discontinue plaintiff’s Glucerna prescription altogether. (ECF No. 100 at 10, ¶ 54.) That same day, defendant Byers took plaintiff’s weight measurement and documented her weight as 135 lbs. (Id., ¶ 55.) On or about August 6, 2021, plaintiff met with Defendant Hosuru. When plaintiff asked to renew her Glucerna 4x prescription, Hosuru declined and told her that she would have to “make up” with the dieticians—referring to Byers and Henrey—because it was a “team decision.” (ECF No. 100 at 11, ¶ 57.) Plaintiff told Hosuru that she was not able to eat the regular food given to her or think clearly because she was not able to get enough food intake. Despite this, Hosuru still placed plaintiff on a calorie restriction, limiting her access to Glucerna. (Id.) On or about October 2023, plaintiff filed an 1824 reasonable accommodation request, requesting: (1) to move from DD1 to DD2 status to receive increased protection and monitoring from the staff, citing that her Autism and ADHD increase her susceptibility to sexual exploitation outside presence of the staff, and (2) single cell status. (ECF No. 100 at 11, ¶ 60.) On or about November 13, 2023, the RAP denied plaintiff’s requests and removed plaintiff from the DDP altogether. (Id., ¶ 61.) The RAP staff present included ADA Coordinator K. Petersen, Chief Physician and Surgeon G. Williams, ADA Analyst L. Bucsit, and Senior Psychologist C. Mohadjer. Plaintiff was removed from the DDP and her DD1 status was removed. Plaintiff no longer receives adaptive supports and correctional officers have threatened to put her in a double- cell, which prompts an increase in symptoms related to PTSD and Autism. (Id. at 11-12, ¶ 61.) II. F

Free access — add to your briefcase to read the full text and ask questions with AI

(PC) Medley v. Pfitzer, (E.D. Cal. 2025).

(PC) Medley v. Pfitzer ((PC) Medley v. Pfitzer) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related